Share
PrintTest Details
Cancer Type
Gastric, Gastroesophageal
Technology Used
IHC
Turnaround Time
5 - 9 days
Use
HER-2-positive carcinomas predict response to humanized monoclonal antibody trastuzumab (Herceptin®) in conjunction with chemotherapy in patients with advanced or metastatic gastric or gastro-esphageal junction carcinoma.
Special Instructions
Please direct any questions regarding this test to oncology customer service at 800-345-4363. Please note: fixation time and fixative used must be indicated on the test request form.
Limitations
Use of fixatives other than 10% formalin, fixation times less than six hours or greater than 48 hours may not yield reliable results.
Methodology
Immunohistochemistry (IHC)
Specimen Requirements
Information on collection, storage, and volume
Specimen
Tumor (formalin-fixed, paraffin-embedded)
Volume
One paraffin block or five unstained, positively charged tissue slides cut at 4 to 5 microns and dried for one hour at 60°C.
Container
Paraffin block transport pouch or slide mailer
Storage Instructions
Maintain specimen at room temperature.
Causes for Rejection
Tumor other than gastric tumor
Collection
FFPE tissue, preserved in 10% neutral buffered formalin, fixed for 18 to 24 hours. ASCO/CAP 2013 guidelines recommend fixation time between six and 72 hours for breast tissue; however, special ASCO/CAP guidelines have not been established for gastric cancer samples.
Related Tests
Find more tests related to this one.
